Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Strides"

94 News Found

Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics
News | January 21, 2023

Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics

The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.


Strides Pharma Global receives AUD 94 mn for sale of Australia's operations
News | December 23, 2022

Strides Pharma Global receives AUD 94 mn for sale of Australia's operations

The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument


Strides receives USFDA approval for Potassium Chloride Oral Solution
Drug Approval | November 19, 2022

Strides receives USFDA approval for Potassium Chloride Oral Solution

The approval further strengthens the Potassium Chloride franchise for the company.


Strides receives USFDA approval for Naproxen Sodium OTC Softgel capsules
Drug Approval | August 19, 2022

Strides receives USFDA approval for Naproxen Sodium OTC Softgel capsules

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma


Strides receives USFDA approval for Cyclosporine Softgel Capsules
Drug Approval | August 03, 2022

Strides receives USFDA approval for Cyclosporine Softgel Capsules

Strides is the first Indian company to get approval for the product.


Strides receives USFDA approval for Ibuprofen OTC oral suspension
Drug Approval | June 12, 2022

Strides receives USFDA approval for Ibuprofen OTC oral suspension

Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.


Strides receives USFDA approval for Ibuprofen Oral Suspension
Drug Approval | May 30, 2022

Strides receives USFDA approval for Ibuprofen Oral Suspension

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)


Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr
News | May 26, 2022

Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr

The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.


Strides receives USFDA approval for Colchicine tablets
Drug Approval | March 11, 2022

Strides receives USFDA approval for Colchicine tablets

Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout


Strides receives USFDA approval for Amantadine Hydrochloride capsules
Drug Approval | February 21, 2022

Strides receives USFDA approval for Amantadine Hydrochloride capsules

To be marketed by Strides Pharma Inc. in the US market